Denali Therapeutics-JPM-202401.pdf

1、CORPORATE OVERVIEWJ.P.MORGAN HEALTHCARE CONFERENCE 2024 DEFEAT DEGENERATION 2024 Denali Therapeutics Inc.1DISCLAIMERSForward-Looking Statements.This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These forward-looking state

2、ments do not relate strictly to historical or current facts and they may be accompanied by such words as“anticipate,”“believe,”“could,”“estimate,”“expected,”“forecast,”“intend,”“may,”“plan,”“potential,”“possible,”future,“will”and other words and terms of similar meaning.All statements other than sta

3、tements of historical facts contained in this presentation,including,without limitation,statements regarding future results of operations and financial position of Denali Therapeutics Inc.(“Denali”or the“Company”);Denalis business strategy and business plans,expected progress and expansion,and expec

4、ted key milestones for Denalis therapeutic portfolio in 2023 and beyond;Denalis ability to execute on its tailored commercial strategies and accelerate commercial launch readiness;expectations relating to the potential for Denalis product candidates to treat various neurodegenerative diseases includ

5、ing MPS I,MPS II(Hunter Syndrome),MPS IIIA(Sanfilippo Syndrome),ALS,MS,PD,AD,FTD-GRN,UC,and related peripheral inflammatory diseases,planned preclinical studies and clinical trials and the expectations regarding the timing and availability of results and data from such studies and trials;plans,timel

6、ines,expectations,breadth of indications,and current and future therapeutic and commercial opportunities related to Denalis Transport Vehicle(TV)platform,including its Enzyme Transport Vehicle(ETV),Antibody Transport Vehicle(ATV),Protein Transport Vehicle(PTV),and Oligonucleotide(OTV)technologies,an